AGY · LONDON STOCK EXCHANGE ·
Allergy Therapeutics
Audited Preliminary Results and Annual Report
Our AI’s take
Allergy Therapeutics reported higher revenue for the year ended 30 June 2026, but its operating loss and operating cash outflow increased.
The full digestion is for members. What is good, what is bad and why, the numbers that matter, and the chart, then ask about it by voice or text.
Join freeNew to announcements? Learn what an RNS is and why prices move.